258497-48-2

Basic information

• Product Name: 6-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-2PYRIDINECARBOXYLIC ACID METHYL ESTER
• Synonyms: 6-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-2PYRIDINECARBOXYLIC ACID METHYL ESTER;METHYL 6-T-BUTOXYCARBONYLAMINO-PYRIDINE-2-CARBOXYLATE;methyl 6-(tert-butoxycarbonylamino)picolinate;2-Pyridinecarboxylic acid, 6-[[(1,1-diMethylethoxy)carbonyl]aMino]-, Methyl ester;methyl 6-tert-butoxycarbonylamino-2-pyridinecarboxylate;methyl 6-({[(tert-butoxy)carbonyl]amino}methyl)pyridine-2-carboxylate
• CAS NO: 258497-48-2
• Molecular Formula: C12H16N2O4
• Molecular Weight: 252.27
• Mol File: 258497-48-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 419.3°Cat760mmHg
• Flash Point: 207.4°C
• Appearance: /
• Density: 1.149g/cm³
• Vapor Pressure: 3.07E-07mmHg at 25°C
• Refractive Index: 1.511
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-2PYRIDINECARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-2PYRIDINECARBOXYLIC ACID METHYL ESTER(258497-48-2)
• EPA Substance Registry System: 6-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-2PYRIDINECARBOXYLIC ACID METHYL ESTER(258497-48-2)

Safety Data

• Hazardous Substances Data: 258497-48-2(Hazardous Substances Data)

Usage

General Description

6-[(1,1-Dimethylethoxy)carbonyl]amino]-2pyridinecarboxylic acid methyl ester is a chemical compound with the molecular formula C14H17N3O4. It is a methyl ester derivative of 6-[(1,1-dimethylethoxy)carbonyl]amino]-2pyridinecarboxylic acid, and is commonly used in pharmaceutical research and development. 6-[[(1,1-DIMETHYLETHOXY)CARBONYL]AMINO]-2PYRIDINECARBOXYLIC ACID METHYL ESTER is often employed as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has potential biological activity, specifically as an inhibitor of specific enzymes or receptors, making it a valuable tool for drug discovery and design. Its precise applications and uses are determined by its specific properties and interactions with various biological targets.

InChI:InChI=1/C13H18N2O4/c1-13(2,3)19-12(17)14-8-9-6-5-7-10(15-9)11(16)18-4/h5-7H,8H2,1-4H3,(H,14,17)

Upstream product

• 67-56-1 methanol 
• 499-83-2 Pyridine-2,6-dicarboxylic acid 
• 258497-21-1 6-[(tert-butoxycarbonyl)amino]-2-pyridinecarboxylic acid 
• 7170-36-7 6-(methoxycarbonyl)pyridine-2-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 36052-26-3 methyl 6-aminopyridine-2-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 23628-31-1 6-aminopicolinic acid 

Downstream Products

• 258497-18-6 (Z)-2-(2-tert-butoxycarbonylaminopyrid-6-yl)-2-(triphenylmethoxyimino)acetic acid 
• 258497-27-7 (6-tert-butoxycarbonylamino-pyridin-2-yl)-trityloxyimino-acetic acid methyl ester 
• 259533-24-9 3-[4-(2-tert-butoxycarbonylamino-ethylsulfanylmethyl)-[1,2,3]thiadiazol-5-ylsulfanyl]-7-[2-(6-tert-butoxycarbonylamino-pyridin-2-yl)-2-trityloxyimino-acetylamino]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 203321-83-9 tert-butyl 6-(hydroxymethyl)-2-pyridinylcarbamate 
• 105243-77-4 (6-(methylamino)pyrid-2-yl)methanol 
• 400781-16-0 tert-butyl (6-(bromomethyl)pyridin-2-yl)carbamate 

Relevant articles and documents

POLY HETEROCYCLIC CONJUGATES AND THEIR PHARMACEUTICAL USES

Compounds of Formula (I) shown below and a pharmaceutical composition containing one of the compounds: Each of the variables is defined herein. Also disclosed is a method of treating a condition associated with uncontrolled cell growth with a compound of Formula (I).

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors.